<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480672</url>
  </required_header>
  <id_info>
    <org_study_id>ADRISK</org_study_id>
    <nct_id>NCT03480672</nct_id>
  </id_info>
  <brief_title>Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant&#xD;
      radiochemotherapy in the treatment of patients with locally advanced intermediate and high&#xD;
      risk head and neck squamous cell carcinoma (HNSCC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>24 months</time_frame>
    <description>time from randomization to the first event (i.e. locoregional or distant recurrence, initiation of a new anti-cancer treatment death from any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aRCH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adjuvant radio-chemotherapy (aRCH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]</intervention_name>
    <description>intravenous application, 12 months, in 3-week cycle (q3w) 200 mg</description>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>adjuvant radiochemotherapy</intervention_name>
    <description>adjuvant radiochemotherapy with cisplatin</description>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
    <arm_group_label>aRCH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Macroscopically complete resection of newly diagnosed (not recurrent, not secondary&#xD;
             primary) advanced squamous-cell carcinoma arising in the oral cavity, oropharynx,&#xD;
             larynx, or hypopharynx&#xD;
&#xD;
          2. Advanced stage III, IVA/B HNSCC according to the TNM classification version 7th&#xD;
             edition (Note! The 8th edition will not be used, please adhere to the national cancer&#xD;
             institute guidelines)&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; performance&#xD;
             status allows adjuvant chemo radiation with cisplatin.&#xD;
&#xD;
          4. Had either intermediate or high-risk characteristics, i.e. any or all of the&#xD;
             following:&#xD;
&#xD;
               -  histologic evidence of invasion of two or more regional lymph nodes&#xD;
&#xD;
               -  extracapsular extension of nodal disease,&#xD;
&#xD;
               -  microscopically involved mucosal margins of resection (R1) or margins of&#xD;
                  resection &lt; 5mm (R0)&#xD;
&#xD;
          5. Had pathological histologic assessment of p16 (only oropharyngeal carcinoma)&#xD;
&#xD;
          6. Be &gt; 18 years of age&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
          8. Demonstrate adequate organ function&#xD;
&#xD;
          9. Female subject of childbearing potential should have a negative pregnancy test within&#xD;
             3 days prior to receiving the first dose of study medication.&#xD;
&#xD;
         10. Female subjects of childbearing potential must be willing to use an adequate method of&#xD;
             contraception, for the course of the study through 120 days after the last dose of&#xD;
             study medication.&#xD;
&#xD;
         11. Reproductive male subjects must agree to use an adequate method of contraception,&#xD;
             starting with the first dose of study therapy through 120 days after the last dose of&#xD;
             study therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent participation in any other interventional clinical trial or participation&#xD;
             in any other interventional trial within one month before enrolment into this trial.&#xD;
&#xD;
          2. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 7 days before enrolment into this trial.&#xD;
&#xD;
          3. Known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          4. Hypersensitivity to Pembrolizumab or comparable medicinal products or any of its&#xD;
             excipients.&#xD;
&#xD;
          5. Prior anti-cancer monoclonal antibody (mAb) therapy within one month before enrolment&#xD;
             into this trial or who has not recovered (i.e., ≤ Grade 1 (NCI CTCAE Grade) at&#xD;
             baseline) from adverse events due to agents administered more than one month earlier.&#xD;
&#xD;
          6. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within one&#xD;
             month before enrolment into this trial or who has not recovered (i.e., ≤ grade 1 (NCI&#xD;
             CTCAE Grade) at baseline) from adverse events due to a previously administered agent.&#xD;
&#xD;
               1. Note: Subjects with ≤ Grade 2 (NCI CTCAE Grade) neuropathy are an exception to&#xD;
                  this criterion and may qualify for the study.&#xD;
&#xD;
               2. Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
          7. Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
          8. Active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             prior to enrolment (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs). Replacement therapy (e g., thyroxine, insulin, or&#xD;
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,&#xD;
             etc.) is not considered a form of systemic treatment.&#xD;
&#xD;
          9. Evidence of interstitial lung disease or history of (non-infectious) pneumonitis that&#xD;
             required steroids within the last 6 months before enrolment into this trial, or&#xD;
             current pneumonitis.&#xD;
&#xD;
         10. Active infection requiring systemic therapy.&#xD;
&#xD;
         11. Suspected lack of compliance&#xD;
&#xD;
         12. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the baseline visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
&#xD;
         13. HIV, HBV or HCV infection&#xD;
&#xD;
         14. Application of a live vaccine within one month of enrolment.&#xD;
&#xD;
         15. Hypersensitivity to cisplatin or any of its excipients&#xD;
&#xD;
         16. Any potential relationship to the investigator/his deputy or to medical staff of the&#xD;
             study team, to the coordinating investigator or is an employee of the study sit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Dietz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Dietz, Prof. Dr.</last_name>
    <phone>0049 34197</phone>
    <phone_ext>21700</phone_ext>
    <email>andreas.dietz@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anett Schmiedeknecht, Dr.</last_name>
    <phone>0049 34197</phone>
    <phone_ext>16256</phone_ext>
    <email>anett.schmiedeknecht@zks.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin; Klinik für Radioonkologie und Strahlentherapie CVK</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Stromberger, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin, CVK und CCM, Klinik für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Dommerich, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld, Onkologie/Hämatologie/ Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Görner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn; Med. Klinik III / ZIM, Hämatologie/Onkologie</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Brossart, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radiologische Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balint Tamaskovics, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH, Klinik für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Möller, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Gauler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kath. Marienkrankenhaus gGmbH, Zentrum für Innere Medizin Hämatologie/Onkologie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Hapke, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Guntinas-Lichius, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Head Medicine and Oral Health, University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Dietz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNIVERSITÄTSKLINIKUM Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Schröder, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim, Hals-Nasen-Ohren Klinik</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Rotter, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ernst von Bergmann Klinikum Potsdam, Zentrum für Hämatologie, Onkologie und Strahlenheilkunde, Klinik für Hämatologie und</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Maschmeyer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Hautmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Katharinenhospital, Klinik für Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Münter, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg; Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Lewitzki, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Andreas Dietz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

